| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6414cf0912e2737a41f574e3435772e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b5454abd09f216530c44daae0e81afa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 |
| filingDate |
2017-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36f7a0eb3edfb096602d4db771b344c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1352df1e94b23f561962a75116e52fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ba4cdc15ef117b5ad7e751328cb1ee6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c01979327a8c6fdbfad79f7c5b761059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dea735790a670ed3aa7f4f93f37e4371
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16a1f86e6eadac614643d93fa2f51b02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80fc7c7f97f2c1bb0e493414a6e7b08e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be4c7514afcb4cb04ac1c2bfe330947d |
| publicationDate |
2018-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201801752-A |
| titleOfInvention |
EGFR antibody-drug conjugate and its application in medicine |
| abstract |
The invention relates to an EGFR antibody-drug conjugate and its application in medicine. Specifically, the present invention relates to an EGFR antibody variant-cytotoxic drug conjugate or a pharmaceutically acceptable salt or solvent compound thereof, and a pharmaceutical composition comprising the foregoing conjugate or a pharmaceutically acceptable salt or solvent compound thereof. And its use as an anticancer drug; especially in the manufacture of a medicament for the treatment of an EGFR-mediated disease or disorder. |
| priorityDate |
2016-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |